Glenmark survives ECB scare

Pharma mid caps have survived well, Glenmark having grown OPM from 11% to 20%. Revenues have comfortably crossed the $200 mln threshold for the Quarter at INR 10 bln up more than 25% and more than INR 2 B in EBITDA 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s